Target Audience
This activity is intended for medical oncologists, hematologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lymphoma.

Learning Objectives
Upon completion of this activity, participants should be able to

• Appraise the scientific rationale for the evaluation of CD20 x CD3 bispecific antibodies for patients with various forms of non-Hodgkin lymphoma, and assess the similarities and differences among various agents in this class.
• Evaluate available research findings with CD20 x CD3 bispecific antibodies for patients with relapsed/refractory (R/R) follicular lymphoma (FL), and identify individuals for whom treatment with this novel approach should be considered.
• Develop an understanding of the available and emerging clinical research database with the use of CD20 x CD3 bispecific antibodies in the management of R/R diffuse large B-cell lymphoma (DLBCL), and optimally incorporate these agents into the current treatment algorithm for this disease.
• Recognize adverse events associated with available and investigational CD20 x CD3 bispecific antibodies, and implement strategies to educate patients and manage complications.
• Recall ongoing studies evaluating promising CD20 x CD3 bispecific antibody-based strategies under investigation for FL, DLBCL and other B-cell lymphomas, and counsel appropriate patients regarding potential clinical trial participation.

CME Credit Form
A CME credit form link will be emailed to each participant within 5 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Dr Brody has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Flinn — Advisory Committee: Vincerx Pharma; Consulting Agreements: AbbVie Inc, BeiGene Ltd, Genentech, a member of the Roche Group, Genmab US Inc, Kite, A Gilead Company (Zuma-22 trial), Vincerx Pharma; Contracted Research: 2seventy bio, AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bio-Path Holdings Inc, Bristol Myers Squibb, Celgene Corporation, Cogent Biosciences, CTI Biopharma, a Sobi company, Curis Inc, Epizyme Inc, Fate Therapeutics, Forma Therapeutics, Forty Seven Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, IGM Biosciences Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, InnoCare Pharma, Janssen Biotech Inc, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Marker Therapeutics Inc, Merck, MorphoSys, Myeloid Therapeutics Inc, Novartis, Nurix Therapeutics Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Rhizen Pharmaceuticals AG, Roche Laboratories Inc, Seagen Inc, Step Pharma, Takeda Pharmaceuticals USA Inc, Tessa Therapeutics, TG Therapeutics Inc, Trillium Therapeutics Inc, Triphase Research and Development Corporation, Verastem Inc, Vincerx Pharma; Nonrelevant Financial Relationships: CALGB, Calibr-Skaggs Institute for Innovative Medicines, City of Hope National Medical Center. Dr Phillips — Advisory Committees: AbbVie Inc, Genentech, a member of the Roche Group, Genmab US Inc, Merck; Consulting Agreements: AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Bristol Myers Squibb, Epizyme Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Pharmacyclics LLC, an AbbVie Company, Seagen Inc, TG Therapeutics Inc; Contracted Research: AbbVie Inc, Genentech, a member of the Roche Group; Steering Committee: Genentech, a member of the Roche Group.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI Biopharma, a Sobi company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporter
This activity is supported by an educational grant from Genentech, a member of the Roche Group.